For the roughly 30 million American adults who have been told their cholesterol is too high but cannot stomach a statin, the treatment menu has been frustratingly short: a modest pill called ezetimibe, expensive injections, or white-knuckling it with diet alone. Results published in May 2025 in The Lancet now add a genuinely new option to that list. A single tablet combining two oral drugs, obicetrapib 10 mg and ezetimibe 10 mg, cut LDL cholesterol by 48.6 percent versus placebo over 12 weeks in the Phase 3 TANDEM trial, a result the investigators say represents the largest LDL reduction ever recorded in a randomized Phase 3 trial of an oral agent without a statin in the regimen.
The data, presented simultaneously as a late-breaking session at the European Atherosclerosis Society Congress 2025 and published in peer-reviewed form, mark a turning point for a drug class that has spent nearly two decades in the penalty box.
What the TANDEM trial actually showed
TANDEM (NCT06005597) randomized patients across four arms: the fixed-dose combination tablet, obicetrapib alone, ezetimibe alone, and placebo. All participants had elevated LDL cholesterol and were not taking statins, either because of intolerance or by clinical decision. The primary endpoint, percent change in LDL-C from baseline at day 84, was pre-specified and measured in a double-blind, placebo-controlled design, the gold standard for minimizing bias in drug trials.
The combination arm delivered a 48.6 percent placebo-adjusted LDL reduction, meaningfully outperforming either component given on its own. The full manuscript, indexed on PubMed, details the statistical methods, confidence intervals, and comparisons across all four arms. A companion study called BROADWAY, also presented at EAS 2025, evaluated obicetrapib in patients already on statins, but the TANDEM result stands out because it targets the population with the fewest good alternatives.
To put the 48.6 percent figure in context: ezetimibe alone typically lowers LDL by about 15 to 20 percent, according to prescribing data and pooled analyses. Injectable PCSK9 inhibitors such as evolocumab and alirocumab can cut LDL by 50 to 60 percent, but they require subcutaneous shots every two to four weeks and carry list prices that have limited uptake. An oral pill that approaches injectable-level efficacy without requiring a statin backbone could reshape how primary-care doctors manage the patients who fall through the cracks of current guidelines.
A drug class that kept failing until now
Obicetrapib belongs to a class called CETP inhibitors, which work by blocking cholesteryl ester transfer protein, a molecule that shuttles cholesterol between lipoprotein particles. The idea is pharmacologically elegant, but the class has one of the roughest track records in modern cardiology.
Pfizer’s torcetrapib was the first to reach large-scale testing. In 2006, its Phase 3 outcomes trial was halted early after the drug raised blood pressure and increased deaths, a result so alarming it nearly killed the entire CETP concept. Roche’s dalcetrapib followed, only to be abandoned in 2012 after showing no cardiovascular benefit despite raising HDL. Eli Lilly’s evacetrapib met the same fate in 2015. Merck’s anacetrapib finally demonstrated a modest reduction in cardiovascular events in the REVEAL trial, but the company chose not to seek approval, citing an uncertain commercial path.
Obicetrapib is a next-generation CETP inhibitor designed to be more selective and potent at lower doses, which its developers at NewAmsterdam Pharma argue reduces the off-target risks that sank earlier compounds. The TANDEM safety summary, published in The Lancet, reported no major red flags over the 12-week treatment period, though the follow-up is too short and the sample too small to rule out the kind of rare adverse events that derailed torcetrapib. Clinicians who remember that history will want longer and larger data before fully trusting the class again.
The questions patients and doctors will ask next
The most important unanswered question is whether cutting LDL by 48.6 percent with this particular mechanism actually prevents heart attacks and strokes. LDL reduction is one of the best-validated surrogate markers in medicine. Decades of statin trials, plus outcomes data on PCSK9 inhibitors, have established that lowering LDL translates into fewer cardiovascular events. But “translates” is not “guarantees,” and the CETP class has already demonstrated that favorable lipid numbers can coexist with neutral or even harmful clinical outcomes.
NewAmsterdam Pharma is running a large cardiovascular outcomes trial called PREVAIL (NCT05202509) that is designed to answer exactly this question. PREVAIL is enrolling thousands of patients with established cardiovascular disease and will track hard endpoints, including heart attack, stroke, and cardiovascular death, over several years. Until PREVAIL reads out, the clinical case for obicetrapib rests on surrogate lipid data, not on proof that it saves lives.
Other open questions include durability of effect beyond 12 weeks, performance across subgroups defined by age, sex, race, and baseline risk, and how the drug interacts with the many medications that cardiovascular patients typically take. The Lancet paper references subgroup analyses, but granular breakdowns have not yet appeared in publicly available materials. Regulatory submissions to the FDA and EMA will presumably include those data, and independent reviewers will scrutinize them closely given the class history.
Where this fits for people who can’t take statins
For the patient sitting in a doctor’s office who has tried two statins and quit both because of muscle pain, the current conversation usually goes something like this: “We can add ezetimibe, which will help a little, or we can talk about PCSK9 injections, which work well but cost more and require needles.” If obicetrapib plus ezetimibe reaches the market as a single daily pill, that conversation changes. A nearly 50 percent LDL reduction from one tablet, no injections, no statin required, would give physicians a practical middle option that did not exist before.
That said, regulatory approval is not guaranteed. The FDA will weigh the TANDEM data alongside the class’s troubled history and will almost certainly want to see at least interim safety signals from PREVAIL before granting a green light. The European Medicines Agency may follow a similar path. Pricing, insurance coverage, and real-world adherence will further determine whether the drug reaches the patients who need it most or becomes another specialty product with limited uptake.
As of June 2026, the peer-reviewed evidence shows that an oral obicetrapib-ezetimibe combination can cut LDL cholesterol by nearly half in 12 weeks without a statin, a result that is both statistically robust and clinically meaningful. The CETP inhibitor class, long written off after a string of high-profile failures, appears to have produced a viable candidate. Whether that candidate can clear the higher bar of preventing cardiovascular events remains the defining question, and PREVAIL is the trial that will answer it.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
